Filter Results:
(663)
Show Results For
- All HBS Web
(663)
- People (2)
- News (225)
- Research (298)
- Events (4)
- Multimedia (12)
- Faculty Publications (179)
Show Results For
- All HBS Web
(663)
- People (2)
- News (225)
- Research (298)
- Events (4)
- Multimedia (12)
- Faculty Publications (179)
- 07 Nov 2015
- News
I Am Paying for Your Expensive Medicine
- September 2002 (Revised August 2014)
- Case
Cardinal Health (A): The Medicine Shoppe Acquisition
By: Regina E. Herzlinger, Miguel Abecasis and Brenda Cheng
Robert Walter, the founder and CEO of Cardinal Health, a pharmaceutical distributor, is contemplating the purchase of Medicine Shoppe, a chain of apothecaries. The purchase might be construed as competition against his own drugstore customers. But one of its many... View Details
Keywords: Mergers and Acquisitions; Business Strategy; Competitive Advantage; Distribution Industry; Pharmaceutical Industry; Retail Industry
Herzlinger, Regina E., Miguel Abecasis, and Brenda Cheng. "Cardinal Health (A): The Medicine Shoppe Acquisition." Harvard Business School Case 303-043, September 2002. (Revised August 2014.)
- February 2009 (Revised December 2009)
- Case
Merck: Global Health and Access to Medicines
By: V. Kasturi Rangan and Katharine Lee
The case describes the effort of Merck, a global leader in pharmaceuticals, in making available its medicines to the poor. The challenge for the company (or for that matter, any pharmaceutical company) is how to integrate its business strategy with its corporate social... View Details
Keywords: Globalized Firms and Management; Health Care and Treatment; Emerging Markets; Corporate Social Responsibility and Impact; Poverty; Business Strategy; Pharmaceutical Industry
Rangan, V. Kasturi, and Katharine Lee. "Merck: Global Health and Access to Medicines." Harvard Business School Case 509-048, February 2009. (Revised December 2009.)
- 11 Dec 2014
- News
Improving the business of medicine
As founder and managing partner of KBL Ventures, Dr. Marlene Krauss (MBA 1967, MD 1979) combines her business and medical training to bring health care device and bio-tech ventures to market. (Published December 2014) View Details
- May 2023 (Revised June 2023)
- Supplement
Novartis (C): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Testing and Trials; Health Care and Treatment; Business Model; Problems and Challenges; Pharmaceutical Industry; Switzerland
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (C): Reimagining Medicine." Harvard Business School Supplement 723-445, May 2023. (Revised June 2023.)
- May 2002 (Revised December 2003)
- Teaching Note
Medicines Company, The TN
Teaching Note for (9-502-006). View Details
- July 2019 (Revised July 2019)
- Teaching Note
Intermountain Healthcare: Pursuing Precision Medicine
By: Richard G. Hamermesh, Robert S. Huckman and Julia Kelley
- 2003
- Other Unpublished Work
Interventional Radiology: Disrupting Invasive Medicine
By: Chirag D Shah, Troyen A Brennan and C. M. Christensen
- 01 Jun 2023
- News
Research Brief: The Best Medicine
As it turns out, innovation doesn’t benefit everyone equally, and a new study tries to understand how that plays out in the pharmaceutical R&D process in the United States. “The numbers are striking,” says Associate Professor Joshua Schwartzstein, pointing to the fact... View Details
- 18 Nov 2015
- News
Kraft foundation gives $20 million to advance personalized medicine
- 6 Jan 2016
- Interview
A Microchip in Your Medicine
By: Richard G. Hamermesh and Brian Kenny
"A Microchip in Your Medicine." Cold Call (podcast), Harvard Business Review Group, January 6, 2016.
- 06 Jan 2016
- Video
A Microchip in Your Medicine
- 23 Jan 2019
- News
The Promise of Personalized Medicine
the foundation now for a bit over a year, and we didn’t get oriented around this personalized medicine mission until a few months in. So, more or less, we’ve been at this personalized medicine bit for about... View Details
- 08 Nov 2018
- Video
Unlocking the Potential of Precision Medicine
- November 2009 (Revised December 2009)
- Case
GTC Biotherapeutics: Developing Medicines in the Milk of Goats
By: Ray A. Goldberg and Sarah Morton
GTC is the first company in the animal world to receive FDA approval of a transgenic pharmaceutical. What are the implications for other firms in plants and animals and their opportunities to produce new medicines in an economical and safe fashion? View Details
Keywords: Health Care and Treatment; Animal-Based Agribusiness; Plant-Based Agribusiness; Science-Based Business; Medical Specialties; Product; Technological Innovation; Health Industry; Pharmaceutical Industry; United States
Goldberg, Ray A., and Sarah Morton. "GTC Biotherapeutics: Developing Medicines in the Milk of Goats." Harvard Business School Case 910-403, November 2009. (Revised December 2009.)
- October 1998 (Revised April 2000)
- Background Note
Complexity and Error in Medicine
By: Richard M.J. Bohmer
Reviews the issues underlying the rate of error in medical practice and discusses the range of potential management interventions to decrease the risk of error. View Details
Keywords: Health Care and Treatment; Management Practices and Processes; Risk and Uncertainty; Complexity
Bohmer, Richard M.J. "Complexity and Error in Medicine." Harvard Business School Background Note 699-024, October 1998. (Revised April 2000.)